Multivariate analysis of factors associated to liver steatosis in the 41 subjects who spontaneously cleared HCV infection.

<p>Multivariate analysis of factors associated to liver steatosis in the 41 subjects who spontaneously cleared HCV infection.</p

Baseline Characteristics of the 41 subjects with spontaneous resolution of HCV infection enrolled in the study.

*<p>: 2 genotype 1b, 1 genotype 1a, 1 genotype 4.</p><p>#: not mutually exclusive.</p

Characteristics of the 41 subjects with spontaneous resolution of HCV infection enrolled in the study according to steatosis. Univariate logistic regression analysis.

<p>#: IL28B genotypes were collapsed into a recessive model and comparisons were performed as CC versus non-CC genotypes (see text).</p

Population kinetic parameters for the best HCV and ALT kinetic model.

<p>Population kinetic parameters for the best HCV and ALT kinetic model.</p

Decrease of viral load and ALT at different time points under treatment according to NS5A-inhibitors and interferon administration.

<p>These graphs shows the median of predictions of ALT and HCV-RNA in different groups of treatment obtained by simulations from the parameter estimates of the two models. ALT, alanine transaminase; IFN, interferon.</p

Biphasic kinetics of HCV-RNA decay, and ALT drop during all-DAA and TVR+PR treatment and follow-up.

<p>In <i>upper panels</i>, median values with 95% confidence interval of HCV-RNA (black dots) and ALT (grey squares) during all-DAAs (panel <b>A</b>) and TVR+PR (panel <b>B</b>) treatment are reported. End of follow-up is at 12 weeks after treatment discontinuation. Black dotted line represents the lower limit of detection of HCV-RNA (12–15 IU/ml). Grey dotted line represents normality range of ALT values in females (45 IU/ml). Histograms in <i>lower panels</i> represent the percentages of patients with HCV-RNA below the lower limit of detection (panel <b>C</b>) and with normal ALT values (panel <b>D</b>) during all-DAAs (black) and TVR+PR (grey) treatment. Normal ALT values were considered as <55 IU/ml in men, and <45 IU/ml in women. ALT, alanine transaminase; DAA, direct-acting antivirals; EOT, end of treatment; IU, international units; LLOD, lower limit of detection (<12–15 IU/ml, not detected); PR, pegylated interferon and ribavirin; TVR, telaprevir. * p-value <0.05 by Fisher exact test; ** p-value ≤0.001 by Fisher exact test.</p

Predicted kinetic profiles obtained by simulations from the viral and ALT kinetic models.

<p>(panel <b>A</b>) Different viral kinetics according to HCV-genotypes, NS5A-inhibitors and interferon administration, (panel <b>B</b>) Different ALT kinetics according to NS5A-inhibitors and interferon administration. ALT, alanine transaminase; IFN, interferon.</p

Cox analysis for factors influencing ALT normalization during treatment.

<p>Cox analysis for factors influencing ALT normalization during treatment.</p

Modifications of liver disease stage following DAA treatment in patients with cirrhosis.

<p>(A) Baseline, post-failure and post-retreatment SVR12 changes of Child Pugh Class; (B) baseline and post-failure changes of Child Pugh Class for patients who were not retreated yet; (C) baseline and post-SVR12 changes of Child Pugh Class for patients who achieved SVR12 following the first DAA treatment. Bold arrows indicate patients who did not change the Child Pugh Class. Dashed arrows indicate patients who worsened the Child Pugh Class, whereas the grey arrows indicate patients who improved the Child Pugh class. In the curly brackets are reported the number of patients for specific changes observed in the Child Pugh classes in the three points of evaluation. n = number of patients.</p

Univariate and logistic regression analysis linking failure with independent variables.

<p>Univariate and logistic regression analysis linking failure with independent variables.</p